长按二维码,关注官方公众号
PANEL DISCUSSION: Decoding Secrets of Modern Medical Innovation
Under the combined effects of policy support, technological progress, and robust demand, the biopharmaceutical industry continues to see emerging opportunities. The sector brings together cutting-edge scientific exploration and attracts considerable capital interest and investment. Scientists’ research is moving from labs to practical applications, benefiting patients. The industry not only needs innovation but also targeted capital investment and effective market integration. Ensuring that these innovations are recognized, supported by capital, and validated by the market is crucial. They should also drive industry advancement while leading to positive societal changes.
Dr. Chris Lai obtained his Ph.D. at the Novartis-MIT Center, and his research is primarily on dynamic modeling, process optimization, and drug crystallization. With a diverse background in pharmaceuticals and business, Dr. Lai has held positions as Active COO at XtalPi, Consultant in McKinsey, Technical Consultant in General Mills, Technical Consultant in NOVARTIS.
In 2020, he co-founded METiS and served as CEO. As a pioneer in AI-driven drug development, Dr. Lai is at the forefront of leveraging artificial intelligence to revolutionize the process of pharmaceutical research and development. Dr. Lai integrates formulation, delivery technology, and machine learning, laying the foundation for METiS technology platform. Leveraging years of entrepreneurial experience and digital strategies, he steers METiS towards rapid growth.
李萌，小药药/荷叶健康创始人兼董事长，光谷3551人才，武汉市第十五届人大代表；入选2024年科创日报“新质生产力价值先锋榜”、财富网“中国40位40岁以下的商界精英“榜。
2015年创建小药药公司，引领企业在四年间成长为中国领先的互联网健康科技企业、全球“独角兽”企业和湖北省首批科创“新物种”独角兽企业。2018年拓展新业务-荷叶健康，依托于集团强大的药品流通能力和用户优势，迅速成为国内领先的“管家式”全方位健康服务平台，入选“中国数字健康百强榜”，目前拥有千万+核心用户，累计服务数亿人次。
Yue joined FORTUNE China in 2019. Before joining FORTUNE China, he was a Journalist for China Newsweek and Editor of China Times. In 2003, Yue graduated from Lanzhou University.
